6-methyl-6-phenyl-4-trifluoromethylhept-1-yn-4-ol | 1245526-87-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-methyl-6-phenyl-4-trifluoromethylhept-1-yn-4-ol
• 英文别名: 6-Methyl-6-phenyl-4-(trifluoromethyl)hept-1-yn-4-ol
• CAS: 1245526-87-7
• 化学式: C₁₅H₁₇F₃O
• 分子量: 270.295
• InChiKey: RQJSVFXNDHMISQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  6-methyl-6-phenyl-4-trifluoromethylhept-1-yn-4-ol 、 叔-丁基-7-氨基-3,4-二氢异喹啉-2(1H)-甲酸 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 以78%的产率得到[4-(4-hydroxy-6-methyl-6-phenyl-4-trifluoromethylhept-1-ynyl)pyridin-3-yl]carbamic acid tert-butyl ester
  参考文献：
  名称：

  Nonsteroidal Dissociated Glucocorticoid Agonists Containing Azaindoles as Steroid A-Ring Mimetics

  摘要：

  Syntheses and structure activity relationships (SA R) of nonsteroidal glucocorticoid receptor (GR) agonists are described. These compounds contain azaindole moieties as A-ring mimetics and display various degrees of in vitro dissociation between gene transrepression and transactivation. Collagen induced arthritis studies in mouse have demonstrated that in vitro dissociated compounds (R)-16 and (R)-37 have steroid-like anti-inflammatory properties with improved metabolic side effect profiles, such as a reduced increase in body fat and scrum insulin levels, compared to steroids.

  DOI：

  10.1021/jm100751q
• 作为产物：
  描述：

  1,1,1-三氟-4-甲基-3-戊烯-2-酮 在 magnesium 、 氢化铝 、 mercury dichloride 作用下， 以 四氢呋喃 为溶剂， 反应 23.0h， 生成 6-methyl-6-phenyl-4-trifluoromethylhept-1-yn-4-ol
  参考文献：
  名称：

  Optimization of Drug-Like Properties of Nonsteroidal Glucocorticoid Mimetics and Identification of a Clinical Candidate

  摘要：

  A series of nonsteroidal dissociated glucocorticoid receptor agonists was optimized for drug-like properties such as cytochrome P450 inhibition, metabolic stability, aqueous solubility, and hERG ion channel inhibition. This effort culminated in the identification of the clinical candidate compound (R)-39.

  DOI：

  10.1021/ml500387y